Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Change in Accured Expenses (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Change in Accured Expenses for 11 consecutive years, with $162591.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 46.65% year-over-year to $162591.0, compared with a TTM value of $152207.0 through Dec 2025, changed 0.4%, and an annual FY2025 reading of $152207.0, changed 0.4% over the prior year.
  • Change in Accured Expenses was $162591.0 for Q4 2025 at Abvc Biopharma, up from -$33632.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $678094.0 in Q2 2023 and bottomed at -$540519.0 in Q3 2021.
  • Average Change in Accured Expenses over 5 years is $50655.3, with a median of $28288.0 recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 4018.9% in 2023, while the deepest fall reached 281.25% in 2023.
  • Year by year, Change in Accured Expenses stood at $165777.0 in 2021, then surged by 106.17% to $341775.0 in 2022, then tumbled by 102.89% to -$9864.0 in 2023, then surged by 1223.99% to $110870.0 in 2024, then soared by 46.65% to $162591.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ABVC at $162591.0 in Q4 2025, -$33632.0 in Q3 2025, and -$16865.0 in Q2 2025.